CureVac Nears Final Chapter with BioNTech Acquisition and Index Removal

The biotechnology firm CureVac is approaching its final days as a publicly traded company on the NASDAQ. The acquisition by competitor BioNTech is now virtually assured, with the overwhelming majority of shareholders having already tendered their shares. This corporate transition coincides with the stock’s imminent removal from a major market index, presenting specific considerations for remaining investors.

BioNTech reported on December 3 that approximately 184 million CureVac shares had been tendered, representing 81.74 percent of the share capital. This figure comfortably surpasses the minimum acceptance threshold for the takeover to proceed. The offer remains open until 0:01 a.m. ET on December 18, 2025, allowing remaining holders to exchange their Read more...